2-(Phenylamino)-Pyrimidin-5-Amides As Cannabinoid 2 Receptors Modulators for the Treatment of Immune or Inflammatory Disorders

A compound of formula (I);

• wherein:
• Y is phenyl, unsubstituted or substituted with one, two or three substituents;
• R1 is selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, or halosubstitutedC1-6 alkyl;
• R2 is (CH2)mR3 where m is 0 or 1;
• or R1 and R2 together with N to which they are attached form an unsubstituted or substituted 4- to 8-membered nonaromatic heterocyclyl ring;
• R3 is an unsubstituted or substituted 4- to 8-membered non-aromatic heterocyclyl group, an unsubstituted or substituted C3-8 cycloalkyl group, an unsubstituted or substituted straight or branched C1-10alkyl, an unsubstituted or substituted C5-7 cycloalkenyl or R5;
• R4 is selected from hydrogen, C1-6alkyl, C3-6 cycloalkyl, or halosubstitutedC1-6alkyl, COCH3, or SO2Me;
• R5 is
• wherein p is 0, 1 or 2, and X is CH2, O, S, SO or SO2;
• R6 is (C3-6)cycloalkyl, 4- to 7-membered non aromatic heterocyclic group or unsubstituted C2-6alkyl or substituted (C1-6)alkyl;
• R7 is OH, C1-6alkoxy, NR8aR8b, NHCOR9, NHSO2R9, SOqR9;
• R8a is H or C1-6alkyl;
• R8b is H or C1-6alkyl;
• R9 is C1-6alkyl;
• q is 0, 1 or 2;
• and pharmaceutically acceptable derivatives thereof,
• wherein R6 is not CHxFn wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3.